Immunotherapy associated with improved survival for patients with melanoma brain metastases
(American Association for Cancer Research) Among patients with cutaneous melanoma who had brain metastases (MBM), first-line treatment with a checkpoint inhibitor was associated with a 1.4-fold increase in median overall survival, according to results from a national cohort.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Immunotherapy | Melanoma | Neurology | Skin Cancer